Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The treatment of bladder pathologies (e.g., tumours, cancers, infections, interstitial cystitis, neurogenic bladder) involves
either oral or intravesical drug delivery. The intravesical delivery has the advantage (i) to reduce systemic side effects, (ii) to
improve bioavailability of macromolecules or drugs with poor solubility and weak permeability, (iii) to directly target the drug
towards the urothelial layers with potential sustained local therapeutic effects. Although intravesical treatments are widely used
in bladder pathologies, the importance of bladder biopharmaceutics is often neglected.
The aims of this study were to assess the tissue permeability of the bladder and to characterize the transport of four drugs
displaying different physico-chemical properties and commonly used in intravesical delivery, through porcine bladder. The
transport of aluminium through porcine bladder was assessed by using a vertical static diffusion cell. Lidocaine hydrochloride,
methylprednisolone hemisuccinate and mitomycin C were tested by using three different experimental setups, including
vertical static diffusion cell, microdialyseur and lab-patented device. Penetration results on different experimental setups were
homogenous suggesting dependency on physico-chemical characteristics of drug and subsequent interaction with bladder wall
structure. Oppositely, permeation varied consistently with experimental setup characteristics (i.e., permeation surface, receptor
fluid volume and hydrodynamic). Mathematical modeling of drug transport through bladder wall is proposed considering
scarce literature on this route of administration. Practical outcome of this study could drive compounding optimization
towards improvement of safety and efficacy in patient undergoing intravesical administration.
Biography
Fabrice Pirot has completed his PhD at the age of 29 years from University of California San Francisco and University of Franche-Comté (France). He is hospital
pharmacist, associated professor and director of a research team focusing on drug transport and biopharmaceutics at Hospices Civils de Lyon and University of
Lyon. He has published more than 50 papers in reputed journals and serving as an editorial board member of repute.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals